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Abstract
Clinical agreement between two quantitative measurements on a group of subjects is generally
assessed with the help of the Bland-Altman (B-A) limits. These limits only describe the
dispersion of disagreements in 95% cases and do not measure the degree of agreement. The
interpretation regarding the presence or absence of agreement by this method is based on
whether B-A limits are within the pre-specified externally determined clinical tolerance limits.
Thus, clinical tolerance limits are necessary for this method. We argue in this communication
that the direct use of clinical tolerance limits for assessing agreement without the B-A limits is
more effective and has tremendous merits. This nonparametric approach is simple, is robust to
the distribution pattern and outliers, has more flexibility, and exactly measures the degree of
clinical agreement. This is explained with the help of two examples, including setups where
clinical tolerance limits can be set up to follow varying trends if required in the clinical context –
a feature not available in the B-A method.
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SUMMARY
What is already known:
Agreement between two quantitative measurements is generally assessed by Bland-Altman (B-A) limits.
This method requires pre-specification of the clinical tolerance limits.
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What this study adds:
Clinical tolerance limits can be directly used for assessing agreement without calculating B-A limits. This
method is nonparametric, more robust, easy, and more appealing.
What should change now:
Agreement should be assessed by the direct use of clinical tolerance limits instead of B-A limits because
of its huge merits.
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A simple and robust alternative to Bland-Altman
method of assessing clinical agreement
1 Background
Although a large body of literature exists on the methods for assessing agreement in different
contexts such as reproducibility1 and bioequivalence2,3, many studies consider the question “Are
two measurements of a characteristic of a subject by two methods, two sites, or by two observers
sufficiently agree with one another?”. The objective of these studies generally is to find whether
one method can be replaced with the other without much loss of information. If a disagreement is
concluded, the source is investigated – whether it is due to lack of accuracy, due to a large
variation, or for any other reason.
When the measurements are quantitative, such as hemoglobin level and creatinine level,
the method of choice for assessing this agreement is the one developed by Bland and Altman4.
The method was extremely successful in making us aware that the agreement between individual
values x and y cannot be inferred by equality of means, and the correlation coefficient is even
worse because it is perfect 1 between x and y = ax + b, i.e., when all the values obtained by one
method are a linear combination of the other and there is no agreement. It was also separately
shown that the regression y = x, with intercept = 0 and regression coefficient = 1, is also not
appropriate for this purpose because this too is based on means5.
The Bland-Altman (B-A) method requires the calculation of the limits (𝑑̅ – 2sd, 𝑑̅ + 2sd),
where 𝑑̅ is the mean and sd is the standard deviation (SD) of the individual differences d = x – y.
These limits are popularly known as Bland-Altman limits of agreement, although they are better
understood as the limits of disagreement since they are based on differences. The value of 𝑑̅ is an
estimate of the bias of one method over the other.
Under the Gaussian assumption, which is likely to hold in this case because x and y are
measuring the same quantity and the difference is likely to be just the measurement error, nearly
95 percent of the differences are likely to be within the B-A limits. An adequate agreement is
inferred when these limits are narrow in the sense that the difference within these limits “would
not affect decisions on patient management”4. Let us call such limits of indifference as clinical
tolerance limits. The authors stated, “How far apart measurements can be without causing
difficulties will be a question of judgment” and suggested, “Ideally, it (the clinical tolerance
limits) should be defined in advance to help in the interpretation of the methods comparison”.
The crucial limitation of the B-A limits is that they end up describing the disagreements
and not measuring the degree of agreement. Even the interpretation regarding agreement or no
agreement entirely depends on the pre-specified limits of clinical tolerance. We argue in this
communication that such limits of clinical tolerance can be directly used for assessing the extent
of the quantitative agreement without calculating the B-A limits. Thus is a nonparametric,
flexible, robust, and simple method and is a step further than the method of coverage probability6
and the probability of agreement7. This direct method may not have attracted attention because it
is too simple, but it has tremendous merits, particularly in situations where clinical needs allow
varying tolerance limits such as more accuracy at critical values and relaxed limits at away
values. This useful feature is not available in other methods. We discuss several merits of this
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direct method and illustrate them with the help of two examples, including setups where the
tolerance limits can be varied for different values of the measurements.

2 Issues with the Bland-Altman Method
The B-A method has tremendous merits. Besides making us aware of the distinction between the
individual agreement and the group agreement, a significant contribution of the B-A method is
the plot of difference against the average of the two values, known as the B-A plot8, which gives
a nice scatter. The plot of y vs. x is not so informative as most values tend to cluster along the y =
x line.
Perhaps no method has universal applicability, and the B-A method also has its share of
problems because of its dependence on strong assumptions that may be unrealistic in many
situations. The following is a list of these problems:
1. Although the stated objective of the B-A method is to find whether one method of
measurement can be replaced by another method, the B-A limits end up only describing
the dispersion of disagreements in 95% of the cases, without telling whether the
agreement exists or not9, nor they measure the degree of agreement.
2. The B-A limits are valid only when the distribution of the differences is Gaussian. If the
distribution is highly skewed, the limits would provide a misleading assessment of the
disagreement. To remedy this, a suitable transformation such as log transformation is
sometimes advocated that may work in some cases but may be tedious in some other
cases such as in the case of left-skewed distribution.
3. The method is based on mean 𝑑̅ of the differences. If some differences are large and
positive, and others negative, they tend to balance out and can give 𝑑̅ nearly equal to
zero. This may provide a false sense of security about the bias and may affect the
interpretation of the agreement.
4. A single genuine outlying difference, which cannot be excluded, can severely distort the
mean and the SD even if most differences are small. This would undesirably inflate the
B-A limits. A similar problem arises when several differences are zero or equal. Both
these are distinct possibilities in an agreement setup. The limits can be wide depending
on the variance of the differences, even if most differences are small, and the estimate of
bias 𝑑̅ may be distorted.
5. Although the B-A limits use 95% coverage that can be varied but 95% coverage seems to
be a rule in applications. This percentage is as arbitrary as 5% level of significance,
which is being severely criticized10. Any other coverage would be equally arbitrary.
6. The usual B-A limits require that the measurements under comparison have the same
precision and it should be the same for smaller values as for larger values11. If one
method has a higher variance than the other, or if the variance varies with the values, the
B-A limits may provide misleading results.
7. The B-A method may lead to overestimation of bias in some cases12.
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8. When one measurement has a constant bias (a) against the other without any variation,
the limits of agreement would be (a to a), which is just a single point. For example, if the
difference is always 5 units, the limits of agreement would be from 5 to 5.
9. The B-A limits are symmetric and governed by 𝑑̅ . The clinical tolerance limits can be
asymmetric in some situations as illustrated in our example in this communication.
10. The method requires the calculation of the 95% confidence interval (CI) of the lower
limit (𝑑̅ – 2sd) and the upper limit (𝑑̅ + 2sd) based on their respective standard errors –
using Student t-distribution13. This assumes the Gaussian distribution of the limits which
may or may not hold. In any case, the calculation of the CI makes it relatively a tedious
procedure, and most method comparison studies skip this step.
11. The most severe problem with this method is the complete dependence of the
interpretation of B-A limits on externally determined clinical tolerance limits. These can
be directly used to assess agreement, as elaborated next. Many agreement studies end up
stating the limits of agreement without specifying the clinical tolerance limit14,15 ignoring
that no agreement study with B-A methods can be complete without setting up clinical
tolerance limits.
12. The B-A method does not consider variation or trends in clinical tolerance limits.
The interpretation of 𝑑̅ ± 2sd for assessing the agreement crucially depends on whether
these limits are within the range of clinical tolerance. If the limits are within clinical tolerance,
the agreement is considered to exist, otherwise not. Thus, this gives a binary result. Bland and
Altman4 give an example of PEFR (peak expiratory flow rate) measured by two methods and
obtained the ‘limits of agreement’ from –79.7 l/min to +75.5 l/min which, in their opinion, are
too wide and would be unacceptable for clinical purposes. Similarly, in their second example on
oxygen saturation measured by two methods, they obtained (– 2.0 to 2.8) as the limits of
agreement and subjectively called them ‘small enough’ in the sense of clinically unimportant and
concluded that the agreement exists. Although they advised setting up the clinical tolerance
limits in advance to help in the interpretation of the methods comparison, a conclusion regarding
agreement or the lack of it was reached in both of their examples without pre-specifying the
clinical tolerance limits. Giavarina9 remarked that “Acceptable limits must be defined a priori
based on clinical necessity, biological considerations, or other goals”. An Editorial in the British
Journal of Anaesthesia16 also mentioned in the context of B-A limits that “The question of how
small is small depends on the clinical context”. Thus, the B-A limits of agreement are relevant
for assessing agreement only when the clinical tolerance limits are predefined.

3 Direct Use of the Clinical Tolerance Limits: A Simple, Nonparametric,
Robust, and More Appealing Alternative for Assessing Agreement
We propose that the prespecified clinical tolerance limits should be directly used to find the
percentage of differences within these limits. Let us call this percentage agreement. This simple
method of assessing agreement, in one go, can take care of almost all the problems listed earlier
for the B-A limits.
Consider a pair of medical measurements (x, y) on a random sample of n subjects. The
natural parameter of interest is the extent of agreement between the two measurements. Because
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of random fluctuations and possibly systematic differences, some differences between the
observed values of x and y will almost invariably occur. Suppose the clinicians decide that this
difference should not be less than 𝐶𝐿 or more than 𝐶𝑈 for it to be acceptable as of no clinical
consequence. For example, in the case of measurement of aspartate aminotransferase (AST) by
two methods, if these limits are set at ±2 U/L, a difference within these limits will be considered
as having no clinical significance. (𝐶𝐿 , 𝐶𝑈 ) are the clinical tolerance limits and they would be
around zero with 𝐶𝐿 negative and 𝐶𝑈 positive but may or may not be symmetric. We shortly give
an example of such asymmetric limits. The limits (𝐶𝐿 , 𝐶𝑈 ) can also be varied for different values
of the measurements. An example of this is also given later in this communication.
Define the extent of agreement 𝜋 = 𝑃(𝐶𝐿 < 𝑑 < 𝐶𝑈 ). The estimate of 𝜋 is the binomial
proportion of the observed differences falling between (𝐶𝐿 , 𝐶𝑈 ) – thus amenable to all kinds of
statistical inference. If somebody wants to be more confident, the 95% confidence lower bound
for 𝜋 can be obtained by one of the several methods but the Wilson score method can be
recommended, which is implementable and generally considered to perform better17. This will
give the bound below which the extent of agreement is extremely unlikely. If somebody wishes
to test the hypothesis that the agreement is at least a given threshold, such as H0: π ≥ π0, this can
be easily done by the exact one-tail test on the binomial probability under the null hypothesis or,
𝑝− 𝜋0
for reasonably large n, by referring z =
to Gaussian distribution, where p is the
√𝜋0 (1−𝜋0 )/𝑛

observed proportion of differences within the specified clinical tolerance limits.
This method measures the strength of agreement instead of a binary yes or no. Many
researchers these days would like to measure the exact degree of agreement and interpret it in
their context. This direct method is simple, nonparametric, and immediately tells the percentage
agreement. The information regarding the percentage of the differences within and beyond
tolerance is more useful in deciding whether the agreement is adequate, and this would assess
clinical agreement in the true sense since it is based on clinical tolerance limits. This method
uses all the individual differences and not their mean and SD. Perhaps many clinicians would
prefer to use the percentage agreement to estimate the degree of the agreement but, in case
needed, the minimal agreement would be estimated by the lower confidence bound.
Although dichotomization has its risks18, for those who prefer binary result as agreement
exists or not, we recommend that at least 90% of differences should be within the clinical
tolerance limits to conclude an adequate agreement. In place of 90%, any other threshold can be
chosen by the investigator depending on the clinical context. Some clinicians would want no
more than 1 or 2 percent differences to go beyond the clinical tolerance for agreement, and some
may be willing to tolerate deviation in10 percent cases or even higher. Such flexibility (and
several other advantages as given later) is available under the direct method but not under the BA method. If a researcher wants to add a condition, such as no difference should be more than
two times the upper or lower tolerance limit, that can also be done in this method. Any big
difference, howsoever isolated, raises the alarm regarding the agreement, and this method can be
used to raise such an alarm.
The tolerance limits may be based on the expected measurement error. In this case, since
positive errors are likely to be as much as negative errors, 𝐶𝐿 = −𝐶𝑈 . The bias 𝑑̅ and the
variation sd can be obtained in case those are of interest for a particular problem although these
are not needed for assessing the degree of agreement by the proposed method. The
nonparametric (Hodges-Lehmann) estimate of the bias, not affected by the distribution pattern or
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the outliers, is the median of the average of all pairs of the differences (di + dj)/2 (i < j)19. There
will be a total of n(n +1)/2 such pairs when there are n subjects in the study. The confidence
interval (CI) can also be obtained.
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Mean + 1.96 SD
- 2 (Clinical tolerance limit)
+5 (Clinical tolerance limit)

25

Difference (mg/dL)

20

(a)

15
10
5

0
-5

50

-10

100

150

200

Mean of values from venous and capillary sample (mg/dL)

Difference
+ 2% (Clinical tolerance limit)
- 2% (Clinical tolerance limit)

25

(b)

Difference (mg/dL)

20
15
10
5
0
-5

50

100

150

200

-10

Mean of values from venous and capillary sample (mg/dL)

Figure 1. (a) Clinical tolerance limits (solid) and Bland-Altman limits (dotted), (b) Clinical
tolerance limits for proportional difference
The B-A plot would help studying the trend and interpreting the results with the direct
method also. In the case of asymmetric tolerance limits, the plot will be as shown by solid lines
in Figure 1(a). There are drawn at tolerance limits instead of 𝑑̅ ± 2sd. If the differences are likely
to be proportional to the magnitude of values, the proportional differences can be examined for
agreement after setting clinical tolerance limits for the proportional differences. In that case, the
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plot would be as in Figure 1(b). These plots are based on the following example we have made
up to illustrate the direct method. We later show that the clinical tolerance limits can be allowed
to follow a linear or nonlinear trend if desirable in a specific clinical context. Such a flexibility
could give a better assessment of the agreement in some cases.
Example 1: Agreement in fasting blood glucose level measured by the conventional venous
sampling and a new glucometer reading of capillary level
Consider the fictitious values in Table 1 of fasting blood glucose levels obtained on 40 unrelated
subjects by the conventional venous sample analyzed in a laboratory (Method-1) and the
capillary sample analyzed by an improvised glucometer at home (Method-2) that claims to
provide adjusted values to match with the venous values. Since the capillary level is known to be
higher, the company claims that the values given by their glucometer can be higher despite
adjustment but will not exceed venous values by more than 5 mg/dL in at least 90% cases. The
clinicians may be willing to accept this kind of error in view of the distinct advantage of
capillary sampling. Suppose the anticipated random variation is not more than 2 mg/dL in either
direction. Higher values by this margin are already covered by +5 limit and we need to make the
provision for lower values only. Thus, the clinical tolerance limits for agreement are (–2, +5)
mg/dL and asymmetric in this case. These are asymmetric. In case the values ‘sufficiently’ agree,
the glucometer, being highly convenient and quick, can replace the current method that requires
venous sampling and involves a laboratory.
In this made-up example, we have intentionally chosen asymmetric clinical tolerance
limits to illustrate the direct method for this situation too, but symmetric limits can also be
chosen.
Table 1. Values of fasting blood glucose level by two methods
Subject
No.

Fasting blood glucose level (mg/dL)
Method-1
Method-2

Difference
(mg/dL)

Percentage
difference (%)

1
2
3
4
5
6
7
8
9
10

106
82
121
95
178
147
135
140
112
126

110
80
126
97
199
145
138
139
115
130

4
-2
5
2
21
-2
3
-1
3
4

3.77
-2.44
4.13
2.11
11.80
-1.36
2.22
-0.71
2.68
3.17

11
12
13
14
15
16
17
18
19
20

130
106
187
77
120
118
67
136
98
102

129
105
195
80
124
121
65
141
99
105

-1
-1
8
3
4
3
-2
5
1
3

-0.77
-0.94
4.28
3.90
3.33
2.54
-2.99
3.68
1.02
2.94

9
21
22
23
24
25
26
27
28
29
30

118
182
167
132
82
79
139
125
119
78

121
180
160
135
82
80
138
127
118
83

3
-2
-7
3
0
1
-1
2
-1
5

2.54
-1.10
-4.19
2.27
0.00
1.27
-0.72
1.60
-0.84
6.41

31
32
33
34
35
36
37
38
39
40

131
145
169
158
144
138
121
107
125
138

132
143
172
157
145
137
131
106
127
142

1
-2
3
-1
1
-1
10
-1
2
4

0.76
-1.38
1.78
-0.63
0.69
-0.72
8.26
-0.93
1.60
2.90

The mean of the differences in Table 1 is 1.98 mg/dL and SD = 4.39 mg/dL. Thus, the B-A
limits of agreement are (–6.81, +10.76). These are plotted as dotted lines in Figure 1(a) (dots
may not be visible as these are very close to one-another). Under the B-A method, it is up to the
researcher to interpret these as sufficiently trivial or not, and conclude the agreement or its lack,
based on subjective assessment. Perhaps most would say that these are too wide, and the values
given by the new glucometer do not agree with the values given by the venous sample.
When the predefined clinical tolerance limits of (–2, +5) are applied (solid in Figure
1(a)), 36 (90%) of 40 values are within these limits in our example. Thus, the agreement exists
by this criterion, which is ostensibly more stringent in this case relative to the B-A limits of
agreement. The conclusion now reached is different than by the B-A method despite stricter
limits. The B-A method also does not provide the strength of agreement, which is assessed as
90% by the direct method in this example. If one wishes to add another condition such as no
difference should be more than 10 mg/dL, then one value with a difference of 21 mg/dL puts a
question mark. A value as high as this raises suspicion that something wrong has happened with
this reading. This could be the culprit for the B-A method also as it severely affects the 𝑑̅ and sd.
If we exclude this value, the B-A limits of agreement become (–4.85, +7.83), which still seem
unacceptably wide for agreement setup in this case but the agreement by the direct method
remains good at 36/39 = 92.3%. When all the values are considered, the 95% Wilson lower
bound tells that the agreement is extremely unlikely to be less than 81% in the concerned
population. If the criterion is at least 90% agreement between the venous and capillary values of
fasting blood glucose, the agreement in this example does not provide sufficient confidence. This
conclusion is different from what was obtained earlier by the point estimate. The HodgesLehmann estimator of bias in this case is 1.5, with a 95% CI from 0.5 to 3.0.
Perhaps a single example based on synthetic data is not enough to demonstrate the merits
of the direct method, but it illustrates how the method can be effectively used in a practical setup.
The enormous merits of this method are enumerated later in this paper.
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Fasting blood glucose level has a vast range of values, say, from 60 to 400 mg/dL,
depending on the condition of the person at the time of the test. It is likely in this case that the
difference between venous and capillary readings will increase as the values increase. Thus, the
proportional difference may be more appropriate, and the B-A limits would be calculated based
on log transformation. There is no need for logarithmic transformation for using the direct
method and the clinical tolerance limits can be defined in terms of percentage. For illustration,
we now take equal clinical tolerance limit on both sides as –2% to +2% of the value obtained by
Method-1, which we consider as the reference in this case. For agreement, these limits should be
narrow since only the random variation is expected in this setup, and we have chosen ±2% for
illustration. For these limits, the plot of the tolerance range is shown in Figure 1(b). Now only 19
(47.5%) differences are within these limits. Generally, this low agreement would not be
acceptable, and we can conclude with this criterion that the agreement is poor for the
proportional changes.
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Figure 2. Varying clinical tolerance limits: (a) increasing percentage with the values of the
measurement, (b) smaller limit for negative differences and larger for positive differences in
terms of percentage
Since the primary objective in the agreement setup is to assess the agreement with respect
to the clinical tolerance and not to describe the extent of disagreement, in place of changing the
B-A limits for different setups, we focus on the rationality in setting up the clinical tolerance
limits. An extremely nice feature of the direct method is its flexibility for setting up the clinical
tolerance limits. These can be based on the clinical implications of the difference between the
two methods under comparison. The limits do not have to be constant or fixed proportion
through the range of values as considered in Example 1 but can be allowed to vary and can
follow a linear or nonlinear trend. Such variation in tolerance limits is easy to implement with
our method but not with the B-A method. For example, in the case of blood glucose levels, one
may allow 2% difference for low values level, gradually increasing to 3% for middling values,
and 4% for high values (Figure 2(a)). We have shown symmetric limits in this figure, but they do
not have to follow a symmetric trend for negative and positive differences. If the clinical context
allows, the lower (or the higher) limit can be set at a constant rate such as 2%, and the upper (or
lower) limit following an increasing or decreasing trend such as in Figure 2(b). In the case of
blood pressure (BP), a clinician may want fairly accurate readings when the level is around the
threshold such as 90 mmHg for diastolic BP because of implications regarding prescribing a
treatment, but may be willing to tolerate higher differences for lower and higher levels. A similar
situation is illustrated in the following example.
Example 2: Agreement between systolic blood pressure (BP) readings by
sphygmomanometer and automatic blood pressure monitor
This example illustrates the method of direct use of clinical tolerance limits when these vary with
the value of the measurement. The data are from Table 1 in the Bland-Altman13 paper for
comparing the systolic BP reading by an observer (J1) and by an automatic monitor (S1) on 85
subjects. It is for these two readings that the authors assessed agreement by B-A limits. These
limits for this data are enormously wide from –54.7 mmHg to +22.2 mmHg (Figure 3(a)). These
limits are inconsequential for our purpose and stated for the sake of completeness.
Suppose the clinicians are not willing to accept more than a 3-mmHg difference between
the readings by two methods under comparison when the systolic BP is around the threshold of
135 mmHg because that has implications for instituting a treatment, but a larger difference can
be allowed when the reading is away from this value because a larger difference at low or high
values does not much affect the clinical assessment. This can give clinical tolerance limits of the
shape given in Figure 3(b). In this figure, the clinical tolerance limits are drawn at (3 + 10% of
the difference from 135) mmHg on either side. Only 15 out of 85 differences are within these
limits of clinical tolerance – the strength of agreement is only 17.6%, and the 95% confidence
lower bound is 12.0%.
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Figure 3. (a) Bland-Altman limits for the agreement between readings by sphygmomanometer
and automatic monitor (data from Table 1 of Bland-Altman 1998), (b) Agreement with clinical
tolerance limits where the limits vary with the value of the measurements

4 Discussion
Statistical methods for assessing agreement have been extensively reviewed6,20.21. Dunn and
Roberts22 and Alanen23 have provided a critique of the B-A method. But the B-A method
continues to be extremely popular with more than 100,000 results in Google search and more
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than 1100 documents in PubMed database (2022). Many workers have spent their time and
energy in explaining the method and in working out its extensions for different setups5,11,13,16,24,25
so much so that a set of guidelines for reporting agreement studies was also proposed26. The
literature is so huge that it is not feasible to review all of that here.
One of the reasons that the B-A method became so popular is its simplicity. Calculate the
limits of (dis)agreement based on the mean and SD of the differences, compare them with the
clinical tolerance limits, and you are done. The method of directly using the clinical tolerance
limits advocated in this paper is even more simple. Just calculate the percentage of differences
falling within the clinical tolerance limits and you are done. The emphasis is on agreement with
respect to the clinical tolerance and not on the dispersion of the differences. Nearest to this
method is the probability of agreement proposed by Steven et al.7. Another close method is the
total deviation index estimated by tolerance intervals27. The latter is for concordance and not
exactly for agreement. Both these methods are based on distributional assumptions, particularly
the Gaussian, and require mean and SD. The direct method is nonparametric and simpler.
The direct method has several merits. Besides not requiring worrying about the
distribution of the differences, it obviates the need to calculate (𝑑̅ ± 2sd) limits. Also, there is no
need to calculate the CIs of these lower and upper limits, which are messy, particularly for
repeated measures13. Our method is not affected by heteroscedasticity either. In case needed, the
heteroscedasticity can be used to determine differential clinical tolerance limits for different
values. The percentage of agreement is a natural parameter, and its estimate is immediately
available that can be used to interpret the adequacy of the agreement. For a binary result, a
minimum of 90% agreement can be used to infer that the agreement is sufficient. This percentage
is as arbitrary as 95% coverage in the case of the B-A limits. There is a flexibility to call ≥90%
agreement as good, 80%-90% as tolerable and 70%-80% unsatisfactory, and <70% as dismal.
Such categorization is not possible with the B-A method.
The clinical tolerance limits do not depend on the variance of the differences whereas the
limits of the agreement do. Also, this method of directly using the clinical tolerance limits is
more robust as there is no need to worry about how outliers or constant values of the differences
are affecting the 𝑑̅ and the sd, and there is no need to estimate the bias unless required for
extraneous reasons. Most importantly, this method is more flexible as asymmetric clinical
tolerance limits or following a specified trend can be easily used if required in the clinical
context. Since the proposed approach is based on individual differences, and not the average and
SD of the differences, this may be more appealing too. The sample size requirement will be the
same as for estimating a population proportion and there is no need to follow the intricate
procedure suggested by Lu et al.25 for the B-A method. When such overriding merits of assessing
the agreement by directly using the clinical tolerance limits as proposed are realized, extensions
to various setups, such as for repeated measures and meta-analysis, can be developed over time.
These could be relatively much easier to use in applications yet achieve the desired objective.
We may further recommend for agreement analysis that the individual differences should
be thoroughly examined irrespective of the method used to assess agreement. The possibility of a
good agreement for low or middling values and poor agreement for high values, or the viceversa, cannot be ruled out, and this will not be detected either by the B-A limits of agreement or
by our direct method. This is a limitation of both the methods. Also, when we conclude a ‘good’
agreement, the range of values under study should be specified. Extrapolation much beyond the
range actually studied is always fraught with unknown uncertainties.
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5 Conclusion
Direct use of clinical tolerance limits is a hugely preferable method for assessing agreement
between two quantitative measurements on the same subjects because this method is natural,
robust, nonparametric, and more flexible compared to the method based on the B-A limits.
Funding; None
Conflict of interest: None
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